British Journal of Clinical Pharmacology · 2005 · 35 citations · 3 references
MedicineGynecologyPharmacotherapyClinical EpidemiologyContraceptionReproductive EpidemiologyDeep Vein ThrombosisPulmonary EmbolismThromboembolic DiseaseThromboembolism PreventionThrombosisVenous ThromboembolismDisease Incidence RateIncidence RateIncidence Rate EstimationIncidence Rate RatioOral Contraceptive EffectsVenous Thromboembolism AssessmentVenous Thromboembolism DetectionVenous Thromboembolism Epidemiology
AIM: To evaluate cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) reported in a prescription event monitoring study of Yasmin, an oral contraceptive. METHODS: Reports of DVT/PE and events suggestive of DVT/PE were followed up by questionnaire. RESULTS: Thirteen cases (DVT five; PE eight), each with possible risk factor(s), were identified in 15 645 females using Yasmin. Applying complete case analysis, the crude incidence rate was 13.7 cases per 10 000 woman-years (95% confidence interval 7.3, 23.4). CONCLUSIONS: Yasmin is associated with venous thromboembolism. An incidence rate has been calculated, but this may be subject to bias and should be interpreted with caution.
3
Deep vein thrombosis and air travel: record linkage study
Chris Kelman · BMJ · 2003 · 120 citations · Full text
Thromboembolism associated with the new contraceptive Yasmin
Kees van Grootheest, Tom Vrieling · BMJ · 2003 · 52 citations · Full text
Medicine, Obstetrics, Pharmacology +17